Skip to the content
Altai Oncology - Softwarelogo darklogo light
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us
Altai Oncology - Softwarelogo darklogo light
Prostate Cancer

New Reference: Enzalutamide with Radium-223 for Prostate Cancer

Ulas D. Bayraktar, MD
2025-06-02
Prostate Cancer

New Reference: Enzalutamide in Recurrent Prostate Cancer

Ulas D. Bayraktar, MD
2023-11-20
Prostate Cancer

New Indication: Talazoparib and Enzalutamide in Metastatic CRPC

Ulas D. Bayraktar, MD
2023-06-24
Abiraterone and cabazitaxel in prostate cancer
Prostate Cancer

New Protocol: Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Ulas D. Bayraktar, MD
2023-06-07
Niraparib in prostate cancer
Prostate Cancer

New Protocol: Niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer

Ulas D. Bayraktar, MD
2023-06-06
Prostate Cancer

New Indication: Maintenance Darolutamide for CRPC

Ulas D. Bayraktar, MD
2023-03-15
Prostate Cancer

New Indication: Darolutamide in Metastatic Hormone-Sensitive Prostate Cancer

Ulas D. Bayraktar, MD
2022-05-20
Prostate Cancer

New Protocol: Abiraterone with DOCEtaxel in CRPC

Ulas D. Bayraktar, MD
2022-05-20
  • Library
  • F.A.Q.
  • Contact Us

Privacy Policy

Altai, Inc (USA)

30 N Gould St, Ste 6801

Sheridan, WY, 82801, USA

Phone: +1 (978) 393 0042

Altay Tıp Sağlık Yazılım AŞ (Türkiye)

Mutlukent Mah Manuk Bey Sk No: 4

Çankaya, Ankara, 06800, Türkiye

Phone: +90 (312) 911 5735

Our Terms & Privacy Policy

Copyright - 2024 - Altai Inc - All rights reserved

Back to top Drag
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us

jghghjghjghhgj